



Simultaneous Detection and Validation of Analytical Markers of *Swertia chirata* by HPLC-DAD to Evaluate the Potency of Extracts and Fractions against Antioxidant Potential

DEEPAK SINGH JANOTI*^{ORCID} and KUMUD UPADHYAYA

Department of Pharmaceutical Sciences, Faculty of Technology, Kumaun University, Nainital-263136, India

*Corresponding author: E-mail: deepakjanoti@kunainital.ac.in

Received: 2 December 2020;

Accepted: 3 February 2021;

Published online: 16 April 2021;

AJC-20313

The present study is based on the selection of extract and fraction of *Swertia chirata* plant for the antioxidant potential with HPLC fingerprinting, which includes the simultaneous detection and quantification of four analytical markers protocatechuic acid (PCA), swertiamarin (SM), mangiferin (MF) and amarogentin (AG) by HPLC-DAD. The yield of water extract (SWA), hydroalcoholic extract (SHA) and fractions of hydroalcoholic extracts were evaluated for their antioxidant potential against 2,2-diphenyl-1-picrylhydrazyl-hydrate free radical assay (DPPH assay), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid radical scavenging assay (ABTS assay), total reducing assay (TRA), ferric reducing antioxidant potential assay (FRAP assay), total antioxidant capacity assay (TAC assay). The hydroalcoholic extracts (SHA) can be a better choice as compared to water extract (SWA) due to higher yield of extract ($13.680 \pm 0.548\%$) and higher antioxidant activity against DPPH assay, ABTS assay, TRA assay, FRAP assay and TAC assay. In hydroalcoholic extract (SHA), ethyl acetate fraction (SEA) showed most potent activity against DPPH ($IC_{50} = 0.008 \pm 0.002$ mg/mL) and ABTS (0.025 ± 0.001 mg/mL). *n*-Hexane fraction of SHA showed higher FRAP (28.664 ± 3.153 μ mol/mL) and TAC (3.263 ± 0.325 μ mol/mL) value (equivalent to ascorbic acid in μ mol/mL) but showed very low yield ($0.468 \pm 0.018\%$), SBU showed higher TRA value (0.413 ± 0.309 mg/mL). The ethyl acetate fraction (SEA) can be a choice for antioxidant as it showed second highest FRAP (19.547 ± 2.119 μ mol/mL) and TAC (2.750 ± 0.466 μ mol/mL) with better yield ($2.473 \pm 0.594\%$) as compared to *n*-hexane (SH) fractions ($0.468 \pm 0.018\%$).

Keywords: *Swertia chirata*, Protocatechuic acid, Swertiamarin, Mangiferin, Amarogentin, HPLC-DAD, Antioxidant assay.

INTRODUCTION

Swertia genus of Gentianaceae family was first introduced by Roxburgh in 1814 [1]. The genus of *Swertia* has vast range of annual and perennial species about 135 species has been reported and out of which 35 species are found in India [2]. The high therapeutic potential of *Swertia* can be attributed to presence of wide and varied chemical constituents such as xanthenes, iridoid glycosides (amarogentin, amaroswerin, swertiamarin, swerosides, etc.), Xanthenes glycosides (mangiferin, etc.) and polyphenolic acid (protocatechuic acid, etc.). Overall there are approximately 419 metabolites of which 40 bioactive compounds are reported from 30 species of *Swertia* genus, which are responsible for the therapeutic activity [3]. *Swertia chirata* a major plant of *Swertia* genus is one among the 32 highly prioritized medicinal herbs from the rich biodiversity of Uttarakhand state (India) as identified by National Medicinal Plant Board, Government of India [4]. The plant is

mentioned in ancient literature viz. Ayurveda (used as decoction for anti-pyretic, anthelmintic, antiperiodic, laxative and in asthma and leucorrhoea) [4], in Unani text it is used as tonic, chronic fever, astringent, sedative to pregnant uterus, inflammation) [5] and in Chinese medicines, it is used for the treatment of scabies, cholecystitis, hepatitis, pneumonia, dysentery and spasm). It is well documented in Indian Pharmacopoeial codex, British and American Pharmacopoeia (used as tincture and infusion) [1,6]. The geographical distribution of plant is mainly from Himalayan region from Kashmir to Bhutan at an altitude of 1200 to 3000 m above sea level. Plant is also found at Khasi hills in state of Meghalaya (India) between the height of 1200-1500 m above sea level [2]. The demand of plant is very high for immunity enhancement property [4].

The bitter principle of *Swertia* genus fall in the class of irridoids glycosides, secoirridoids glycosides and biphenyl glycosides. The characterization of irridoids and secoirridoids due to the presence of iridane and secoiridane moiety of mono-

terpenoids as they cyclopentane nucleus. Details class of phytochemicals of genus can be characterize as xanthonoids, iridoids, flavonoids, secoiridoids glycosides, terpenoids, alkaloids, some lignans, lactones and some other compounds [7,8].

The screening of phytochemicals by HPLC is useful for the quantitative analysis of the phytochemicals present in the sample. Chemical fingerprint of chromatogram is used for the quality assessment of raw herbs by qualitative and quantitative analysis [9,10]. Present study is based on the phytochemical screening of four analytical markers, their quantification in extracts and fractions of *Swertia chirata* plant by HPLC-DAD method, validation of method and evaluation for their antioxidant properties using different assays. The validation of phytochemicals of *Swertia* species by HPLC is already reported [11]. The present works include the simultaneous detection of protocatechuic acid (PCA) with three other bioactive compounds amarogentin (AG), swertiamarin (SM) and mangiferin (MF). All parameters of ICH guideline have been performed (limit of detection, specificity, limit of quantification, accuracy, precision, repeatability, intermediate precision, reproducibility, linearity, range and robustness) to validate the HPLC-DAD method.

EXPERIMENTAL

Collection of plant: The plant specimen was collected in the month of September 2020 from Bageshwar district, India and authenticated at botanical survey of India, Dehradun with the accession of 177. Rest of specimen were allowed to shade dry. Air dried powdered material of *Swertia chirata* plant allowed for hot extraction (reflux condensation) with aqueous and hydroalcoholic solvent. Aqueous extract (SWA) and hydroalcoholic extract (SHA) dried under reduced pressure with complete dried on water. Fractionation of hydroalcoholic extract (SHA) was done by evaporation of about 3/4th volume of solvent from the extracted medium under reduced pressure and allowed to perform the successive fractionation with hexane (SH), chloroform (SCL), ethyl acetate (SEA), butanol (SBU) and remaining (SRE). After fractionation, the extract fractions were dried and yields were also calculated.

HPLC quantifications: SHIMADZU Prominence-I system LC2030C 3D Japan liquid chromatography, with quaternary pump, PDA detector (model: SPD M20A), auto sampler, C18 column (dimension 250mm × 4.6 mm internal pore size 5µm), Lab solution (software) was used for the analysis of samples. Amarogentin, swertiamarin, protocatechuic acid, mangiferin and trifluoroacetic acid were procured from Sigma-Aldrich, and the solvents *viz.* methanol, hexane, chloroform, butanol, *etc.* used were of HPLC grade.

Chromatographic conditions: Trifluoroacetic acid (TFA) solution (1%) was prepared and taken as solvent A and filtered through 0.2 µm membrane filter. Acetonitrile:water (70:30) was taken as solvent B. Gradient programme was set as solvent B initially start with 15% and increases to 20%, for 5 min, further increased to solvent B to 70% from 5 to 30 min and allowed to hold for 35 min, and finally 15% of solvent B was allowed from next 35 to 40 min. Detection of all the analytical marker was done at 240 nm by PDA detector at ambient temperature.

Preparation of samples: All the extracts and fractions were dissolved in methanol (HPLC grade), and filtered with 0.2 µm membrane filter before injecting the solutions.

Preparation of standard solution: All four analytical markers protocatechuic acid (PCA), amarogentin (AG), swertiamarin (SM) and mangiferin (MF) were dissolved in methanol separately to prepare a stock solution. The stock solution of each analytical marker were mixed to obtain different required concentrations.

Method validation: Validation of method was done on the basis of ICH guidelines [12] and USP methods, which include specificity, limit of quantification (LOQ), limit of detection (LOQ), precision at limit of detection level, matrix effect, linearity, precision, accuracy, robustness and uncertainty [12].

Antioxidant activity

DPPH radical scavenging assay: 1,1-Diphenyl-2-picrylhydrazyl (0.2 mM) solution was prepared in methanol as a stock solution. All the extracts and fractions were dissolved in methanol to prepare a stock solution of 10 mg/mL, serial dilution of stock solution of extracts and fractions was done on the basis to achieve IC₅₀ (inhibition control 50%) value of 0.1 mM DPPH with SWA, SHA, SH, SCL, SEA, SBU, SRE dilutions at 517 nm. Ascorbic acid were used as a standard [13].

ABTS radical scavenging assay: A 14 mM of ABTS (2,2'-azinobis(3-ethyl benzothiazoline-6-sulfonic acid) and 4.8 mM potassium persulphate solutions were prepared as stock solutions. Both the stock solutions were mixed equally to prepare a ABTS reagent. The reagent was allowed to stand for 16 h before use and then 1/5th dilution was made to keep the absorbance of ABTS reagent at 734 nm. All the extracts and fractions were dissolved in methanol to prepare 10 mg/mL stock solutions. Serial dilutions of stock solution of SWA, SHA, SCH, SCL, SEA, SBU, SRE were done to achieve IC₅₀ (inhibition control 50%) at 734 nm. Ascorbic acid were used as a standard [13,14].

Total reducing assay: The stock solution of 10 mg/mL of extracts and fractions were prepared in methanol serial dilution of all extracts and fractions were made on the basis to keep IC₅₀ value at 700 nm. A 2.5 mL of each dilutions of SWA, SHA, SCH, SCL, SEA, SBU, SRE were taken in test tube and 2.5 mL of sodium phosphate buffer (0.2 mM pH 6.6) and 2.5 mL of potassium ferricyanide (1%) were added. The solution mixture in each test tube was incubated at 50 °C for 20 min and then 2.5 mL 10% trichloroacetic acid was added into each test tube. Each test tube was centrifuged at 3000 rpm for 10 min and then the collected supernatant was half-fold diluted by water. Then 1 mL of 1% FeCl₃ was added in each dilution. The formation blue colour measured at 700 nm. Ascorbic acid was used as standard [13,14].

Ferric reducing antioxidant potential (FRAP) assay: FRAP reagent was prepared by mixing of 25 mL of acetate buffer (30 mM, pH 3.6) with 2.5 mL of TPTZ [2,4,6-Tris-(2-pyridyl)-s-triazine] solution (10 mM in 40 mM hydrochloric acid) followed by the addition of 2.5 mL freshly prepared ferric chloride solution (20 mM). The solution was allowed to incubate at 37 °C for 15 min before use. Ascorbic acid were taken as standard was serially diluted to obtain a uniform graph against

FRAP reagent at 593 nm. All the extracts and fractions were dissolved in methanol to prepare the stock solutions of 10 mg/mL. The concentration dilutions of extracts and fractions were adjusted to obtain a significant absorbance for the determination of FRAP value equivalent to ascorbic acid from standard graphs [13,14].

Total antioxidant capacity assay (phosphomolybdate assay): Phosphomolybdate reagent (solution of 4 mM ammonium molybdate, 28 mM sodium phosphate and 0.6 M sulphuric acid) was prepared. Ascorbic acid was used as standard and dissolved in methanol to prepared 10 mg/mL stock solution. A 1 mg/mL were used as working solution to obtain a uniform graph against phosphomolybdate reagent at 695 nm. All extracts and fractions were dissolved in methanol to prepare a stock solution of 10 mg/mL. The concentration dilutions of extracts and fractions were adjusted to obtain a significant absorbance for the determination of total antioxidant capacity (TAC) value equivalent to ascorbic acid from standard graphs [13,14].

RESULTS AND DISCUSSION

Extracts and fractions of *Swertia chirata* plant yield:

Total yield of SWA and SHA extracts was found to be $11.093 \pm 0.369\%$ and 13.680% , respectively. The SHA extract showed a higher yield as compared with SWA hence given higher preference as compared with SWA extract. Serial fractionation of SHA extract was done and final yield with *n*-hexane was found to be $0.468 \pm 0.018\%$ (SH), with chloroform $1.232 \pm 0.042\%$ (SCL), with ethylacetate $2.473 \pm 0.594\%$ (SEA), with butanol $2.643 \pm 0.662\%$ (SBU) and the remaining material $4.378 \pm 0.098\%$ (SRE) were achieved.

HPLC quantifications: Screening and quantification of four analytical marker compounds in extracts and fractions were done by HPLC-DAD, and the chromatogram of the standard, extracts and fractions are shown in Fig 1. The SWA and SHA extract showed the presence of all four analytical marker compounds (PCA, SM, MF and AG) (Table-1). The SHA consists higher extent of PCA (0.081 ± 0.002), SM ($0.953 \pm 0.015\%$), MF ($1.031 \pm 0.008\%$), whereas in SWA, AG ($0.158 \pm 0.001\%$) content was found higher than SHA (0.104 ± 0.005). In between fractions, PCA and AG were not found in SH, similarly, PCA was absent in SBU. Among all the fractions, SCL showed higher PCA ($1.225 \pm 0.036\%$), In the same way, SM ($0.440 \pm 0.007\%$) and MF ($3.693 \pm 0.033\%$) in SBU, and AG ($3.640 \pm 0.146\%$) in SEA. Remaining material after fractionation (SRE) did not show any presence of analy-

tical marker compounds as observed in the SRE chromatogram (Fig. 1).




Fig. 1. HPLC chromatogram of standard (STD), SWA extract, SHA extract, SH fraction, SCL fraction, SEA fraction, SBU fraction and the remaining (SRE) material

Method validation

Specificity: The specificity were passed by determining the percentage RSD (relative standard deviation), tailing factor, USP plate count of individual marker compounds as mentioned in Table-2.

TABLE-1
CONTENT OF PCA, SM, MF AND AG IN EXTRACTS AND FRACTIONS BY HPLC-DAD DETECTION

Extracts	PCA	SM	MF	AG
SWA	0.062 ± 0.002	0.084 ± 0.006	0.182 ± 0.004	0.158 ± 0.001
SHA	0.081 ± 0.002	0.953 ± 0.015	1.031 ± 0.008	0.104 ± 0.005
Fractions obtained from hydroalcoholic extract				
SH	Absent	0.074 ± 0.001	0.126 ± 0.001	Absent
SCL	1.225 ± 0.036	0.362 ± 0.039	0.118 ± 0.001	0.182 ± 0.008
SEA	0.254 ± 0.042	0.044 ± 0.005	1.443 ± 0.010	3.640 ± 0.146
SBU	Absent	0.440 ± 0.007	3.693 ± 0.033	0.322 ± 0.013
SRE	Absent	Absent	Absent	Absent

TABLE-2
SPECIFICITY OF PCA, SM, MF AND AG PERFORMED IN TERMS OF RSD, USP PLATE COUNTS AND TAILING FACTOR

Compound name	Conc. (ppm)	Average RT	%RSD	Average plate count (USP)	%RSD	Average tailing factor	%RSD	Range
PCA	10	8.160	0.151	17167	0.983	1.135	0.910	0.80-2.0
SM	10	10.468	0.092	38612	0.635	1.146	0.242	0.80-2.0
MF	10	11.712	0.063	69509	1.225	1.203	0.180	0.80-2.0
AG	10	19.803	0.012	183713	0.932	1.141	0.078	0.80-2.0

Linearity: A significant linearity were obtained between the solutions of ranges of 0.1 to 5 µg/mL of concentration (100 to 2 ng of injecting concentration). As per standard limit of 0.99, the present method shows a good linearity (Table-3).

Sensitivity: Limit of detection (LOD) and limit of quantification (LOQ) of all the four analytical marker compounds were range between 5 to 0.01 µg/mL. The S/N ratio was shown as an appropriate range between 5 to 0.1 µg/mL concentration, which were found suitable for all four analytical marker compounds for the LOD and LOQ detection (Table-4).

Precision: All the four compounds were performed at two different concentrations (4 and 10 µg/mL) and each sample was repeated six times in a day for intraday precision and repeated six times for three consecutive days for interday precision. The RSD results of retention time of compounds were found in the permissible limit (Table-5).

Accuracy: Four different concentrations between 50 to 150% in spikes were taken for the recovery analysis. A significant recovery were found within the standard limit of 80 to 120% (Table-6). PCA showed a 102.62% recovery with 1.91%

TABLE-3
LINEARITY OF IN TERMS OF CORRELATION REGRESSION COEFFICIENT (R²) OF RETENTION TIME, SLOPE OF CURVE AND INTERSECT OF PCA, SM, MF AND AG MARKERS COMPOUNDS

Compound name	Linearity range (µg/mL)	Injection volume conc. (ng)	R ²	Slope	Intercept
PCA	0.1-5	2-100	0.9994	50834	-894.85
SM	0.1-5	2-100	0.9990	28325	2685.4
MF	0.1-5	2-100	0.9950	88958	2302.7
AG	0.1-5	2-100	0.9995	35374	223.44

TABLE-4
SENSITIVITY ANALYSIS OF HPLC-DAD IN TERMS OF LIMIT OF DETECTION (LOD), LIMIT OF QUANTIFICATION OF PCA, SM, MF AND AG OBTAINED BY S/N RESPONSE OF HPLC SOFTWARE

Compound name	Linearity range (µg/mL)	Injection volume conc. (ng)	R ² (conc. vs. S/N ratio)	Regression equation	LOD	LOQ
PCA	0.1-5	2-100	0.9917	y = 2.3554x ± 0.5445	1.042	4.014
SM	0.1-5	2-100	0.9923	y = 1.15965x ± 0.4956	1.569	5.953
MF	0.1-5	2-100	0.9978	y = 6.5253x ± 0.9376	0.316	1.389
AG	0.1-5	2-100	0.9978	y = 2.3961x ± 0.3368	1.111	4.033

TABLE-5
INTRA-DAY AND INTERMEDIATE PRECISION ANALYSIS OF PCA, SM, MF AND AG

Compound name	Concentration (µg/mL)	Intra-day precision		Inter-day precision		Limit (%RSD) NMT
		Mean area	%RSD	Mean area	%RSD	
PCA	4	198395	0.667	19288	1.083	10
	10	499469	0.077	499455	0.030	10
SM	4	106212	0.344	105468	0.725	10
	10	278226	0.090	279126	0.358	10
MF	4	323158	0.633	319972	0.862	10
	10	907246	0.203	907886	0.062	10
AG	4	139690	0.630	139651	0.631	10
	10	343136	0.369	344112	0.252	10

TABLE-6
ACCURACY IN TERM OF RECOVERY OF PCA, SM, MF AND AG WAS OBTAINED FROM SPIKE SOLUTION

Sample name	Concentration (%)	Recovery (%)	%RSD	Limit (% recovery)
PCA	50, 100, 120, 150	102.62	1.91	80 to 120
SM	50, 100, 120, 150	102.62	1.46	80 to 120
MF	50, 100, 120, 150	102.85	1.91	80 to 120
AG	50, 100, 120, 150	102.59	1.41	80 to 120

RSD, SM showed 102.62% recovery with 1.46% RSD, MF 102.85% recovery with 1.91% RSD and AG 102.59% recovery with 1.41% RSD.

Robustness: The capacity of analytical method to remain unchanged with some deliberate changes in flow rate (1.1 and 0.9 mL/min). Solvent A (0.11% TFA and 0.09% TFA) and solvent B (acetonitrile:water 77:23 and acetonitrile:water 67:37), each change parameter were repeated six time to determine the %RSD, USP plate count and tailing factor. With solvent A variability 0.259% to 0.464% RSD, 15794 to 167727 USP plate counts, 1.101 to 1.225 tailing factor and solvent B variability 0.137 to 1.056% RSD, 1.143 to 1.305 tailing factor were observed (Table-7). The %RSD of retention time, USP plate counts and tailing factor suggested that robustness parameter test was passed in the validation.

Antioxidant assay

DPPH assay: In this assay, standard IC₅₀ of ascorbic acid was found to be 4.164 µg/mL. For the tested samples, the IC₅₀

of SHA extract was found to be 0.063 ± 0.010 mg/mL, which was higher than SWA 1.154 ± 0.106 mg/mL. Among the SHA fractions, SEA showed the highest DPPH reducing activity at 0.008 ± 0.002 mg/mL followed by SCL 0.019 ± 0.002, SBU 0.050 ± 0.002 and SH 0.097 ± 0.060 and lowest reducing activity was found in SRE IC₅₀ 9.194 ± 2.984, respectively.

ABTS assay: Using ABTS assay, the IC₅₀ of ascorbic acid was found to be 5.597 µg/mL. The IC₅₀ value of SHA extract was 0.243 ± 0.030 mg/mL, which is also found higher activity than SWA 6.499 ± 0.567 mg/mL. Among the fractions, SEA showed the highest ABTS reducing activity at 0.025 ± 0.001 mg/mL, followed by SBU 0.157 ± 0.002, SH 0.158 ± 0.024 and SCL 0.162 ± 0.008 and the lowest ABTS were found to be in SRE 31.00 ± 2.215. Hence, ABTS activity was found in SHA extract than SWA extract, and SEA fraction shows higher activity than other fractions.

Total reducing assay: Antioxidant assay by TRA were performed with standard ascorbic acid, extracts and fractions.

TABLE-7
ROBUSTNESS EXPRESSED IN TERMS OF FLOW RATE VARIABILITY, SOLVENT A CONCENTRATION VARIABILITY, SOLVENT B RATION VARIABILITY FOR PCA, SM, MF AND AG MARKERS COMPOUNDS

Parameters		Working parameter		– Changes		+ Changes			
Flow		1 mL/min		0.9 mL/min		1.1 mL/min			
Solvent A concentration TFA (trifluoroacetic acid)		0.1% TFA		0.09% TFA		0.11% TFA			
Solvent B concentration (acetonitrile:water)		70:30		67:37		77:23			
Flow	Variability	Compounds name	Area	Area %RSD	Limit NMT (%)	Plate counts (USP)	NLT	Tailing factor	Range
Flow (mL/min)	0.09	PCA	3101146	0.187	10	16064	1800	1.215	0.8-2.0
		SM	1705261	0.305	10	39794	1800	1.139	0.8-2.0
		MF	5267706	0.353	10	75293	1800	1.184	0.8-2.0
		AG	2195773	0.429	10	167727	1800	1.104	0.8-2.0
	1	PCA	2641308	1.157	10	18907	1800	1.184	0.8-2.0
		SM	1441355	1.841	10	35070	1800	1.162	0.8-2.0
		MF	4447413	1.056	10	63374	1800	1.274	0.8-2.0
		AG	1847368	0.984	10	157552	1800	1.147	0.8-2.0
	1.1	PCA	1199858	0.139	10	22220	1800	1.256	0.8-2.0
		SM	714685	0.305	10	46476	1800	1.219	0.8-2.0
		MF	2322348	1.056	10	72418	1800	1.327	0.8-2.0
		AG	1742173	0.204	10	166592	1800	1.173	0.8-2.0
Solvent A (conc. of TFA)	0.09	PCA	1562179	0.262	10	16064	1800	1.215	0.8-2.0
		SM	863651	0.302	10	39794	1800	1.139	0.8-2.0
		MF	2767538	0.259	10	75293	1800	1.184	0.8-2.0
		AG	1127306	0.335	10	167727	1800	1.104	0.8-2.0
	0.1	PCA	1302366	0.252	10	17074	1800	1.167	0.8-2.0
		SM	716896	0.358	10	42182	1800	1.160	0.8-2.0
		MF	2316205	0.209	10	77026	1800	1.263	0.8-2.0
		AG	920504	1.187	10	185000	1800	1.144	0.8-2.0
	0.11	PCA	1574045	0.301	10	15794	1800	1.225	0.8-2.0
		SM	867755	0.298	10	38821	1800	1.146	0.8-2.0
		MF	2775963	0.413	10	75275	1800	1.182	0.8-2.0
		AG	1129790	0.464	10	166761	1800	1.101	0.8-2.0
Solvent B (acetonitrile: water)	63:37	PCA	1571508	0.617	10	18362	1800	1.153	0.8-2.0
		SM	854738	0.584	10	54362	1800	1.188	0.8-2.0
		MF	2673752	1.056	10	84929	1800	1.305	0.8-2.0
		AG	1119493	0.542	10	189468	1800	1.173	0.8-2.0
	70:30	PCA	1782994	1.579	10	12328	1800	1.149	0.8-2.0
		SM	979786	1.429	10	22528	1800	1.103	0.8-2.0
		MF	3105847	1.407	10	42494	1800	1.177	0.8-2.0
		AG	1398623	1.486	10	103208	1800	1.462	0.8-2.0
	77:23	PCA	1670677	0.761	10	15827	1800	1.230	0.8-2.0
		SM	914045	0.137	10	25756	1800	1.177	0.8-2.0
		MF	2938784	0.615	10	47629	1800	1.239	0.8-2.0
		AG	1185690	0.444	10	155547	1800	1.143	0.8-2.0

The intensity of blue colour formation in terms of IC₅₀ of ascorbic acid were found at 156.68 µg/mL. In the test sample, the SHA IC₅₀ was 3.554 ± 1.783 mg/mL, which is higher than SWA 6.432 ± 3.217 mg/mL. Among all the fractions, SBU showed the highest TRA reducing activity 0.413 ± 0.309 mg/mL, followed by SCL 0.974 ± 0.585, SEA 1.230 ± 0.615 and SH 4.443 ± 3.866 and no reducing activity was found in SRE fraction.

FRAP assay: A FRAP values in µmol/mL equivalent to ascorbic acid of all extracts and fractions were determined through the equation obtained from the standard curve of ascorbic acid against FRAP reagent. The SHA possessed a higher FRAP value 18.830 ± 1.242 than SWA 3.280 ± 0.462. Similarly, SH showed a highest FRAP value 28.922 ± 3.153 followed by SEA 19.547 ± 2.119, SCL 15.664 ± 1.945 and SBU 15.195 ± 0.911, while SRE showed a very low FRAP value 0.049 ± 0.003 as compared to others fractions.

Total antioxidant capacity (phosphomolybdate assay): The TAC values of all the extracts and fractions were determined through line equation obtained by the standard ascorbic acid against phosphomolybdate reagent. The TAC values of SWA, SHA, SH, SCL, SEA, SBU, SRE were determined in terms of equivalent to ascorbic acid. In this assay also, SHA extract possessed a higher TAC value 1.035 ± 0.006 (equivalent to ascorbic acid) than SWA extract 0.132 ± 0.132. Similarly, SH shows the highest TAC value 3.263 ± 0.325 followed by SEA 2.750 ± 0.466, SCL 1.945 ± 0.226 and SBU 1.728 ± 0.258, while SRE exhibited a very low TAC value 0.132 ± 0.013 as compared to others fractions.

Phytochemical analysis shows that presence of all the analytical markers in both water (SWA) and hydroalcoholic (SHA) extracts. Among these four analytical markers, protocatechuic acid (PCA), swertiamarin (SM) and mangiferin (MF) were found higher in SHA extract whereas amarogentin (AG) content was found higher only in SWA extract. The extract yields were also found higher in SHA in comparison to SWA.

Among all the four fractions (SH, SCL, SEA, SBU) and remaining after fractionation (SRE) of SHA, SH exhibited a lowest yield in presence of SM and MF, but possessed the highest activity against FRAP and TAC assay, whereas SEA showed the second highest yield and also showed a good activity against DPPH, ABTS and second highest activity against FRAP and TAC after SH.

Conclusion

All four analytical markers compounds *viz.* protocatechuic acid (PCA), swertiamarin (SM), mangiferin (MF) and amarogentin (AG) have been quantified and validated in each extracts and fractions by HPLC-DAD method. The hydroalcoholic extract (SHA) showed higher activity as compared with water extract (SWA) against the five different antioxidant assays. Fractions shows different response of the ethyl acetate fraction (SEA) shows most potent activity against DPPH, ABTS which is very near to standard (IC₅₀ = 4.144 µg/mL DPPH, IC₅₀ = 5.597 µg/mL ABTS). Thus, SEA fractions can be a choice in case of free radicals inflammation, against FRAP and TAC assays while the *n*-hexane (SH) showed a higher FRAP, TAC

with equivalent to standards (ascorbic acid µmol/mL) value as compared to other fractions. The SEA fraction also show second highest FRAP and TAC value with significant yield, hence, in case of electron donor antioxidant assay, SH fraction can be used in TRA assay. The butanol fraction (butanol) showed a mild antioxidant activity when compared to standard (standard IC₅₀ = 156.68 µg/mL). The remaining fraction (SRE) of SHA extract exhibited the highest yield (4.378 ± 0.098%) followed with SBU, SEA, SCL extracts. A very poor yield of *n*-hexane (SH) extract (0.468 ± 0.018%) was obtained when compared with the yield of SEA fraction, thus SEA fraction also can be used as second but more prominent as a choice for FRAP and TAC due to the higher yield (2.473 ± 0.5794%). Hence comparatively choice between fractions, SEA can be better choice for selection as antioxidant, except in case TRA assay were SBU fractions can be a better choice. In extracts, SHA is best choice as compared to SWA extracts because of higher yield and higher activity against all the studied antioxidant assays.

ACKNOWLEDGEMENTS

The authors acknowledge to Botanical Survey of India, Dehradun, India for the authentication of medicinal plant.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interests regarding the publication of this article.

REFERENCES

1. A. Aleem and H. Kabir, *J. Drug Deliv. Ther.*, **8**, 73 (2018); <https://doi.org/10.22270/jddt.v8i5-s.1957>
2. V. Kumar and J. Van Staden, *Front. Pharmacol.*, **6**, 308 (2016); <https://doi.org/10.3389/fphar.2015.00308>
3. W. Yu, M. Ma, X. Chen, J. Min, L. Li, Y. Zheng, Y. Li, J. Wang and Q. Wang, *Am. J. Chin. Med.*, **45**, 1 (2017); <https://doi.org/10.1142/S0192415X1750001X>
4. V. Sharma, N. Srivastava, B. Kamal, A.K. Dobriyal and V.S. Jadon, *J. Pharm. Res.*, **4**, 1784 (2011).
5. J.S. Negi, P. Singh and B. Rawat, *Curr. Res. Chem.*, **3**, 1 (2010); <https://doi.org/10.3923/crc.2011.1.15>
6. Anonymous, Wealth of India, A Dictionary of Indian Raw materials & Industrial products. Second Supplement series (Raw material). National Institute of Science Communication and Information Resources Council of Scientific and Industrial Research (CSIR), New Delhi, vol. 3, pp 159-161 (2009).
7. P. Kaur, D. Kumar Pandey, R.C. Gupta and A. Dey, *Ind. Crops Prod.*, **132**, 449 (2019); <https://doi.org/10.1016/j.indcrop.2019.02.055>
8. G. Brahmachari, S. Mondal, A. Gangopadhyay, B. Mukhopadhyay, D. Gorai, S. Saha and A.K. Brahmachari, *Chem. Biodivers.*, **1**, 1627 (2004); <https://doi.org/10.1002/cbdv.200490123>
9. M. Singh, R. Mohan, S. Mishra, N. Goyal, K. Shanker, N. Gupta and B. Kumar, *J. Pharm. Biomed. Anal.*, **164**, 302 (2019); <https://doi.org/10.1016/j.jpba.2018.10.054>
10. H. Yin, L. Zou, Y. Sheng, X. Bai, Q. Liu and B. Yan, *Anal. Sci.*, **34**, 207 (2018); <https://doi.org/10.2116/analsci.34.207>
11. J.S. Negi, P. Singh, G.J. Pant and M.S.M. Rawat, *Med. Plants J. Phytomed. Rel. Ind.*, **1**, 97 (2009); <https://doi.org/10.5958/j.0975-4261.1.2.012>
12. ICH Guideline, Validation of Analytical Procedures: Text and Methodology, International Conference on Harmonization, Topic Q2 (R1), Geneva, Switzerland, November (2005).
13. I.F.F. Benzie and J.J. Strain, *Methods Enzymol.*, **299**, 15 (1999); [https://doi.org/10.1016/S0076-6879\(99\)99005-5](https://doi.org/10.1016/S0076-6879(99)99005-5)
14. D. Ahmed, M. Khan and R. Saeed, *Antioxidants*, **4**, 394 (2015); <https://doi.org/10.3390/antiox4020394>